Association between P2Y1 and P2Y12 polymorphisms and acute myocardial infarction and ADP-induced platelet aggregation

• Published in: BMC cardiovascular disorders Vol. 23; no. 1; pp. 41 - 8
• Main Authors: Su, Chunyan, Zhang, Zhishan, Chen, Jintu, Tian, Mengcha, Wu, Conglian, Zhang, Tao
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.01.2023; BioMed Central; BMC
• Subjects: Acute myocardial infarction; Adenosine diphosphate; Adenosine Diphosphate - pharmacology; Blood Platelets; Body mass index; Cardiovascular disease; Cholesterol; Diabetes; DNA sequencing; Gene polymorphism; Haplotypes; Heart attacks; High density lipoprotein; Humans; Hypertension; Myocardial infarction; Myocardial Infarction - diagnosis; Myocardial Infarction - genetics; P2Y1 gene; P2Y12 gene; Platelet Aggregation; Platelet Aggregation Inhibitors - pharmacology; Polymorphism; Polymorphism, Genetic; Regression analysis; Risk factors; Stroke; Vein & artery diseases; China; United States > US; Platelet aggregation; P2Y1 gene; Acute myocardial infarction; P2Y12 gene; Polymorphism
• ISSN: 1471-2261; 1471-2261
• DOI: 10.1186/s12872-023-03075-4

The objective of this study was to investigate the relationship between P2Y1 and P2Y12 genotypes and the risk of acute myocardial infarction (AMI) in the Quanzhou population and to determine associations between P2Y1 and P2Y12 genotypes and ADP-induced platelet aggregation in this population. All subjects were screened for P2Y1 (c.1622A > G) and P2Y12 (H1/H2, c.34C > T) polymorphisms by direct DNA sequencing. The maximal platelet aggregation rate (MAR) in AMI patients (n = 61) and healthy control subjects (n = 50) was measured by a PL-12 platelet function analyzer, and adenosine diphosphate (ADP) (5 μmol/L) was used as an agonist. The haploid H2 allele in the P2Y12 gene was more frequent in patients with AMI than in control subjects (OR 1.887, P = 0.005). The P2Y12 H2 haplotype was significantly associated with AMI in the codominant (P = 0.008), dominant (OR 2.103, P = 0.003), and overdominant models (OR 2.133, P = 0.003). After adjusting for potential confounders, H2 haplotype carriers had a 2.132-fold increased risk for AMI (OR 2.132, P = 0.012) compared with noncarriers. Moreover, we observed that the ADP-induced MAR in the carriers of the H2 haplotype from the control group was somewhat higher than that in noncarriers of this group (P = 0.020). However, we failed to demonstrate that the P2Y1 H1/H2 polymorphism affected ADP-induced MAR in AMI patients. Additionally, P2Y1 c.1622A > and P2Y12 c.34C > T polymorphisms were not associated with the risk of AMI or ADP-induced MAR in either group. Therefore, our results suggest that the P2Y12 H2 haplotype was associated with a higher risk of AMI, while its effect on increased ADP-induced platelet aggregation remains to be investigated. Thus, the P2Y12 H2 haplotype may be a potential marker for AMI.